Lung allograft is believed to be initiated between donor lung macrophages and dendritic cells leading to presentation of major histocompatibility complex (MHC) antigens that stimulate host lymphocytes. Direct or indirect allo-recognition of donor MHC antigens or proteins homologous to MHC antigens (MHC-""""""""like"""""""") is believed to perpetuate the rejection process. Conversely, indirect allo-recognition of MHC or MHC-""""""""like"""""""" peptides in the pre-transplant period may prevent rejection activity. Although donor MHC antigens are usually the target of allo-immune responses. alpha-chains of type V and XI collagen, that may be homologous to MHC proteins, are also recognized as antigens during lung allograft rejection. Therefore, pre-transplant immunization with peptides of type V or VI collagen may modulate the rejection response. We have developed a murine model in which the instillation of allogeneic (C57BL/6,H-2,1-a/b) bronchoalveolar lavage cells (96% macrophages, 1-2% dendritic cells) into the lungs of recipient mice (BALB/c, H-2/d, 1-a/d) reproduce the histology and cellular and humoral immunology of acute lung allograft rejection observed in humans, as well as, immune responses to type V and XI collagen. Utilizing this unique model the current proposal tests the hypothesis that allogeneic lung macrophages and dendritic cells mediate lung allograft rejection, and examines the molecular mechanisms responsible for the rejection process by examining the following specific aims:
Aim 1. To determine the interactions between donor lung macrophages and dendritic cells and the microenvironment of the lung that lead to up-regulated allo-immune responses in the allograft, soluble signals produced locally in response to the instillation of allogenic macrophages and dendritic cells in recipient lungs will be examined for their role in facilitating rejection. 2. To determine the role of direct and indirect allo- recognition in the pathogenesis of lung allograft rejection, the requirement for functional donor accessory cells or recipient accessory cells in graft destruction will be tested.
Aim 3. To determine the role of MHC alloantigens, and CD4+ and CD8+ lymphocytes in the rejection process, lung accessory cells which do not express MHC II or MHC I or both antigens will be instilled into the lungs of recipient mice followed by an assessment of the cellular and humoral immune changes and histology in recipient lungs.
Aim 4. To determine if indirect allo- recognition of peptides that may be homologous to MHC antigens prior to transplantation down regulates the rejection response, BALB/c mice will be immunized with peptides of type V and XI collagen prior to instilling C57BL/6 bronchoalveolar lavage cells into BALB/c mice followed by an assessment of the histology, and immunology of acute rejection. The goal of these studies is to discern the immune mechanisms of lung allograft rejection at a molecular level so targets may be identified for therapeutic intervention to prolong the survival of lung allograft recipients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL060797-03
Application #
6363555
Study Section
Lung Biology and Pathology Study Section (LBPA)
Program Officer
Noel, Patricia
Project Start
1999-03-15
Project End
2003-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
3
Fiscal Year
2001
Total Cost
$250,198
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Wu, Qiang; Gupta, Pawan Kumar; Suzuki, Hidemi et al. (2015) CD4 T Cells but Not Th17 Cells Are Required for Mouse Lung Transplant Obliterative Bronchiolitis. Am J Transplant 15:1793-1804
Wilkes, David S (2011) Chronic lung allograft rejection and airway microvasculature: is HIF-1 the missing link? J Clin Invest 121:2155-7
Shilling, Rebecca A; Wilkes, David S (2011) Role of Th17 cells and IL-17 in lung transplant rejection. Semin Immunopathol 33:129-34
Braun, Ruedi K; Molitor-Dart, Melanie; Wigfield, Christopher et al. (2009) Transfer of tolerance to collagen type V suppresses T-helper-cell-17 lymphocyte-mediated acute lung transplant rejection. Transplantation 88:1341-8
Shilling, R A; Wilkes, D S (2009) Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 9:1714-8
Yamada, Yoshito; Sekine, Yasuo; Yoshida, Shigetoshi et al. (2009) Type V collagen-induced oral tolerance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts. J Immunol 183:237-45
Iwata, Takekazu; Philipovskiy, Alexander; Fisher, Amanda J et al. (2008) Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 181:5738-47
Chiyo, M; Iwata, T; Webb, T J et al. (2008) Silencing S1P1 receptors regulates collagen-V reactive lymphocyte-mediated immunobiology in the transplanted lung. Am J Transplant 8:537-46
Bobadilla, Joseph L; Love, Robert B; Jankowska-Gan, Ewa et al. (2008) Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med 177:660-8
Iwata, Takekazu; Chiyo, Masako; Yoshida, Shigetoshi et al. (2008) Lung transplant ischemia reperfusion injury: metalloprotease inhibition down-regulates exposure of type V collagen, growth-related oncogene-induced neutrophil chemotaxis, and tumor necrosis factor-alpha expression. Transplantation 85:417-26

Showing the most recent 10 out of 30 publications